Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

820 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease.
Cummings JL, Atri A, Feldman HH, Hansson O, Sano M, Knop FK, Johannsen P, León T, Scheltens P. Cummings JL, et al. Among authors: hansson o. Alzheimers Res Ther. 2025 Jan 8;17(1):14. doi: 10.1186/s13195-024-01666-7. Alzheimers Res Ther. 2025. PMID: 39780249 Free PMC article. Clinical Trial.
Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.
Rabinovici GD, Knopman DS, Arbizu J, Benzinger TLS, Donohoe KJ, Hansson O, Herscovitch P, Kuo PH, Lingler JH, Minoshima S, Murray ME, Price JC, Salloway SP, Weber CJ, Carrillo MC, Johnson KA. Rabinovici GD, et al. Among authors: hansson o. J Nucl Med. 2025 Jan 8:jnumed.124.268756. doi: 10.2967/jnumed.124.268756. Online ahead of print. J Nucl Med. 2025. PMID: 39778970
Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.
Rabinovici GD, Knopman DS, Arbizu J, Benzinger TLS, Donohoe KJ, Hansson O, Herscovitch P, Kuo PH, Lingler JH, Minoshima S, Murray ME, Price JC, Salloway SP, Weber CJ, Carrillo MC, Johnson KA. Rabinovici GD, et al. Among authors: hansson o. Alzheimers Dement. 2025 Jan 8. doi: 10.1002/alz.14338. Online ahead of print. Alzheimers Dement. 2025. PMID: 39776249 Review.
Benchmarking Alzheimer's disease prediction: personalised risk assessment using polygenic risk scores across various methodologies and genome-wide studies.
Bellou E, Kim W, Leonenko G, Tao F, Simmonds E, Wu Y, Mattsson-Carlgren N, Hansson O, Nagle MW, Escott-Price V; Alzheimer’s Disease Neuroimaging Initiative. Bellou E, et al. Among authors: hansson o. Alzheimers Res Ther. 2025 Jan 6;17(1):6. doi: 10.1186/s13195-024-01664-9. Alzheimers Res Ther. 2025. PMID: 39762974 Free PMC article.
Plasma p-tau217 in Alzheimer's disease: Lumipulse and ALZpath SIMOA head-to-head comparison.
Pilotto A, Quaresima V, Trasciatti C, Tolassi C, Bertoli D, Mordenti C, Galli A, Rizzardi A, Caratozzolo S, Zancanaro A, Contador J, Hansson O, Palmqvist S, De Santis G, Zetterberg H, Blennow K, Brugnoni D, Suárez-Calvet M, Ashton NJ, Padovani A. Pilotto A, et al. Among authors: hansson o. Brain. 2024 Dec 16:awae368. doi: 10.1093/brain/awae368. Online ahead of print. Brain. 2024. PMID: 39679606
Strong diagnostic performance of plasma ptau217 for CSF biomarker-defined young-onset Alzheimer disease in a diagnostically heterogeneous clinical cohort.
Eratne D, Li QX, Lewis C, Dang C, Kang MJY, Grewal J, Loi S, Walterfang M, Evans AH, Malpas CB, Pedrini S, Martins R, Chatterjee P, Zetterberg H, Blennow K, Berkovic SF, Santillo AF, Collins S, Masters CL, Velakoulis D; MiND Study Group. Eratne D, et al. J Neurol. 2024 Dec 12;272(1):25. doi: 10.1007/s00415-024-12732-3. J Neurol. 2024. PMID: 39666133
820 results